DaVita vs Bio-Techne

DaVita (DVA), health care, and Bio-Techne (TECH), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Bio-Techne is worth $11.4B on the stock market and DaVita $11B: Bio-Techne is valued at 4% more. DaVita trades at 13.2 times earnings and Bio-Techne at 66.8; operating margins in their latest fiscal years were 15.0% and 20.7%. Over the past year DaVita's share price has moved +49.5% and Bio-Techne's +25.2%.

Key facts

DaVita market value
$11B
Bio-Techne market value
$11.4B
DaVita P/E
13.2
Bio-Techne P/E
66.8
DaVita revenue
$13.6BFY to 2025-12-31
Bio-Techne revenue
$1.2BFY to 2026-06-30
Superinvestors holding both
0

Market values as of .

DaVita vs Bio-Techne: every measure side by side
Measure DaVita Bio-Techne
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312026-06-30
Size
Market cap$11Blower$11.4Bhigher
Revenue$13.6Bhigher$1.2Blower
Earnings$746.8Mhigher$181.9Mlower
Employees78,000higher3,000lower
Total assets$17.5Bhigher$2.6Blower
Valuation
P/E13.2lower66.8higher
P/S0.8lower9.4higher
P/B—5.3
Dividend yield0.00%lower0.33%higher
Profitability
Operating margin15.0%lower20.7%higher
Balance sheet
Net assets-$651.1Mlower$2.1Bhigher
Total liabilities$16.3Bhigher$478.5Mlower
Total debt$10.3Bhigher$200Mlower
Cash on hand$676.4Mhigher$264.7Mlower
Price change
Today+0.25%higher0.00%lower
1 year+49.5%higher+25.2%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

DaVita only (2)

Percentages are each holding's share of that investor's reported portfolio. Who owns DVA · Who owns TECH

Further comparisons

Learn

Questions and answers

Which is bigger, DaVita or Bio-Techne?

By market value, Bio-Techne is the larger: $11.4B against $11B for DaVita. By revenue in its latest fiscal year, DaVita is the larger: $13.6B against $1.2B for Bio-Techne.

Which has the higher P/E ratio?

Bio-Techne: 66.8, against 13.2 for DaVita. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Bio-Techne: 20.7%, against 15.0% for DaVita. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Bio-Techne: 0.33%, against 0.00% for DaVita. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which has more debt?

DaVita: $10.3B, against $200M for Bio-Techne. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both DaVita and Bio-Techne?

None of the tracked superinvestors holds both in their latest 13F filing. 2 hold DaVita and 7 hold Bio-Techne.

Cite this page

Funkfolio, “DaVita vs Bio-Techne”, data as of 17 November 2026. https://funkfolio.com/compare/dva-vs-tech

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.